Alaunos Therapeutics Announces Registered Direct Offering

FORT LAUDERDALE, Fla., Sept. 18, 2026 /CourierPR/ -- Alaunos Therapeutics, Inc., a biotechnology company focused on developing novel therapeutics, has announced the pricing of a registered direct offering. The company entered into definitive agreements with institutional investors for the sale of 380,469 shares of its common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at a price of $1.46 per share. The aggregate gross proceeds from this offering are expected to be approximately $1,120,000, before deducting placement agent fees and offering expenses.

The offering is expected to close on or about September 21, 2026, subject to the satisfaction of customary closing conditions. The securities will be offered and sold pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289748), initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 11, 2025, and became effective on December 1, 2025.

Dawson James Securities, Inc. is acting as the sole placement agent for the offering. Interested parties should read the prospectus supplement and the accompanying prospectus, which will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus may also be obtained from the offices of Dawson James Securities, Inc. at 2700 N Military Trail, Suite 100, Boca Raton, FL, 33431, or by email at [email protected].

The Company intends to use the net proceeds from the offering primarily for general working capital and corporate purposes. Alaunos Therapeutics, Inc. is advancing its obesity and metabolic disorders program, which includes the evaluation of ALN1003, an oral small-molecule candidate being developed as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology.

This press release includes forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Alaunos Therapeutics, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.